Reply to ‘Factors influencing the outcome of polypoidal choroidal vasculopathy following combined treatment with photodynamic therapy and intravitreal ranibizumab’

被引：0
|
作者：
M Ho
E C Lo
A L Young
D T L Liu
机构：
[1] Dennis Lam & Partners Eye Center,
来源：
Eye | 2015年 / 29卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1239 / 1239
相关论文
共 50 条
  • [21] Two-year visual outcome of polypoidal choroidal vasculopathy treated with photodynamic therapy combined with intravitreal injections of ranibizumab
    Hata, Masayuki
    Tsujikawa, Akitaka
    Miyake, Masahiro
    Yamashiro, Kenji
    Ooto, Sotaro
    Oishi, Akio
    Nakata, Isao
    Takahashi, Ayako
    Yoshimura, Nagahisa
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2015, 253 (02) : 189 - 197
  • [22] Prognostic factors for combined ranibizumab and prompt verteporfin photodynamic therapy for polypoidal choroidal vasculopathy
    Hsia, Yun
    Chan, Li-Wei
    Yang, Chang-Hao
    Yang, Chung-May
    Hsieh, Yi-Ting
    PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2019, 27 : 227 - 233
  • [23] Functional changes following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy
    Chengguo Zuo
    Feng Wen
    Jiaqing Li
    Yan Liu
    Shixian Long
    Shizhou Huang
    Meng Li
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248 : 191 - 196
  • [24] Functional changes following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy
    Zuo, Chengguo
    Wen, Feng
    Li, Jiaqing
    Liu, Yan
    Long, Shixian
    Huang, Shizhou
    Li, Meng
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2010, 248 (02) : 191 - 196
  • [25] Choroidal Thickness Changes After Intravitreal Ranibizumab and Photodynamic Therapy in Recurrent Polypoidal Choroidal Vasculopathy
    Maruko, Ichiro
    Iida, Tomohiro
    Oyamada, Hiroshi
    Sugano, Yukinori
    Ojima, Akira
    Sekiryu, Tetsuju
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2013, 156 (03) : 548 - 556
  • [26] Combined Photodynamic Therapy With Verteporfin and Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy
    Sato, Taku
    Kishi, Shoji
    Matsumoto, Hidetaka
    Mukai, Ryo
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2010, 149 (06) : 947 - 954
  • [27] Efficacy of Intravitreal Bevacizumab Combined With Photodynamic Therapy for Polypoidal Choroidal Vasculopathy
    Gomi, Fumi
    Sawa, Miki
    Wakabayashi, Taku
    Sasamoto, Yuzuru
    Suzuki, Mihoko
    Tsujikawa, Motokazu
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2010, 150 (01) : 48 - 54
  • [28] Visual outcomes of polypoidal choroidal vasculopathy treated with intravitreal ranibizumab with or without photodynamic therapy
    Tan, Colin S.
    Ngo, Wei Kiong
    Lim, Louis W.
    ACTA OPHTHALMOLOGICA, 2018, 96 (02) : e254 - e255
  • [29] Prognostic factors associated with long-term results of intravitreal ranibizumab combined with photodynamic therapy for treatment-naive polypoidal choroidal vasculopathy
    Okubo, Atsushi
    Obata, Ryo
    Azuma, Keiko
    Inoue, Tatsuya
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [30] Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
    Wataru, Kikushima
    Sugiyama, Atsushi
    Yoneyama, Seigo
    Matsubara, Mio
    Fukuda, Yoshiko
    Parikh, Ravi
    Sakurada, Yoichi
    PLOS ONE, 2020, 15 (02):
12345